GHDX : Summary for Genomic Health, Inc. - Yahoo Finance

U.S. Markets close in 6 hrs 9 mins

Genomic Health, Inc. (GHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
31.29+0.34 (+1.10%)
As of 9:49AM EDT. Market open.
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close30.95
Bid30.54 x 700
Ask31.46 x 100
Day's Range31.04 - 31.39
52 Week Range22.90 - 33.96
Avg. Volume132,203
Market Cap1.07B
PE Ratio (TTM)-74.50
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire2 hours ago

    Published Outcomes Results from SEER Registries Indicates That Many Node-positive Breast Cancer Patients Can Avoid Chemotherapy Based on Oncotype DX® Results

    REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast Recurrence Score® in guiding chemotherapy treatment decisions in certain node-positive patients. Consistent with previously published findings in Nature Partner Journals Breast Cancer, the new SEER Registries analysis demonstrates that breast cancer patients with limited node-positive disease who have low Breast Recurrence Score™ (RS) results have an excellent chance of breast cancer-specific survival (BCSS). These data, along with results from 14 additional Oncotype DX® studies in breast cancer patients, were also presented at the 15th St. Gallen International Breast Cancer Conference in Vienna.

  • Genomic Health's Cancer Test Business Strong, Expenses High
    Zacks2 days ago

    Genomic Health's Cancer Test Business Strong, Expenses High

    On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.

  • Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue?
    Zacks2 days ago

    Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue?

    Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.